CoChat

Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer’s disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allosterically modulate γ-secretase, reducing the net production of Aβ42 and to a lesser extent Aβ40, while concomitantly augmenting production of Aβ38 and Aβ37. This GSM demonstrated robust time- and dose-dependent efficacy in acute, subchronic, and chronic studies across multiple species, including primary and secondary prevention studies in a transgenic mouse model. The GSM displayed a >40-fold safety margin in rats based on a comparison of the systemic exposure (AUC) at the no observed adverse effect level (NOAEL) to the 50% effective AUC or AUCeffective, the systemic exposure required for reducing levels of Aβ42 in rat brain by 50%.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20202560

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Structures of pyridazine-derived GSMs and the compounds’ effect on Aβ levels. (A) Compound structures are shown. The IC50 values for the inhibition of Aβ42 and Aβ40 secretion and the EC50 values for the potentiation of Aβ38 in vitro are indicated. IC50 and EC50 values represent the concentration in nanomolars of compound required for reducing either Aβ42 or Aβ40 levels or increasing Aβ38 levels by 50% and are the mean of at least four determinations. (B and C) Concentration response curves of compounds 2 and 3 using SHSY5Y-APP cell-based screening assays. Aβ42, Aβ40, and Aβ38 peptide levels were determined using Meso Scale Sector 6000 Multiplex assays. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM.
Figure 1. Structures of pyridazine-derived GSMs and the compounds’ effect on Aβ levels. (A) Compound structures are shown. The IC50 values for the inhibition of Aβ42 and Aβ40 secretion and the EC50 values for the potentiation of Aβ38 in vitro are indicated. IC50 and EC50 values represent the concentration in nanomolars of compound required for reducing either Aβ42 or Aβ40 levels or increasing Aβ38 levels by 50% and are the mean of at least four determinations. (B and C) Concentration response curves of compounds 2 and 3 using SHSY5Y-APP cell-based screening assays. Aβ42, Aβ40, and Aβ38 peptide levels were determined using Meso Scale Sector 6000 Multiplex assays. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 2. Dose-dependent efficacy of GSMs compound 2 and compound 3 in mice. (A) Levels of Aβ42 and Aβ40 in plasma and brain following daily oral administration of either vehicle (V) or compound 2 to male C57BL/6J mice (n = 10/dose) were measured following a 9-d treatment course. (B) Levels of Aβ42 and Aβ40 in plasma and brain following daily oral administration of either vehicle or compound 3 to male C57BL/6J mice (n = 10/dose) were measured following a 9-d treatment course. Mouse brain Aβ42 levels were below the threshold of detection for both compounds. Aβ42 and Aβ40 peptide levels were determined using MSD multiplex assays. Data are expressed in picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. ****, P < 0.0001. ND, below detectable limit of the assay.
Figure 2. Dose-dependent efficacy of GSMs compound 2 and compound 3 in mice. (A) Levels of Aβ42 and Aβ40 in plasma and brain following daily oral administration of either vehicle (V) or compound 2 to male C57BL/6J mice (n = 10/dose) were measured following a 9-d treatment course. (B) Levels of Aβ42 and Aβ40 in plasma and brain following daily oral administration of either vehicle or compound 3 to male C57BL/6J mice (n = 10/dose) were measured following a 9-d treatment course. Mouse brain Aβ42 levels were below the threshold of detection for both compounds. Aβ42 and Aβ40 peptide levels were determined using MSD multiplex assays. Data are expressed in picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. ****, P < 0.0001. ND, below detectable limit of the assay.CC BY-NC-SA · PubMed Central
Figure 3. Time course of efficacy following a single oral dose of GSM compound 2. (A and B) Male C57BL/6J mice (n = 7/time point) were administered compound 2 at 5 mg/kg (A) or 10 mg/kg (B). Following a single dose of compound 2 or vehicle (V) by oral gavage, mice were euthanized at the indicated time point (1–48 h) and the levels of Aβ42 and Aβ40 peptides were quantitated in plasma and in brain extracts using Meso Scale Sector 6000 Multiplex assays. Data are expressed in picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.0001. ND, below detectable limit of the assay.
Figure 3. Time course of efficacy following a single oral dose of GSM compound 2. (A and B) Male C57BL/6J mice (n = 7/time point) were administered compound 2 at 5 mg/kg (A) or 10 mg/kg (B). Following a single dose of compound 2 or vehicle (V) by oral gavage, mice were euthanized at the indicated time point (1–48 h) and the levels of Aβ42 and Aβ40 peptides were quantitated in plasma and in brain extracts using Meso Scale Sector 6000 Multiplex assays. Data are expressed in picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ****, P < 0.0001. ND, below detectable limit of the assay.CC BY-NC-SA · PubMed Central
Figure 4. Time course of efficacy following a single oral dose of GSM compound 3. Male C57Bl6 mice (n = 7/time point) were dosed with 10 mg/kg of compound 3 or vehicle by oral gavage. Animals were then sacrificed at the indicated time point (1–48 h), and the levels of Aβ42 and Aβ40 peptides in plasma and brain extracts were quantified using Meso Scale Sector 6000 Multiplex assays. Data are expressed in picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; ****, P < 0.0001. ND, below detectable limit of the assay.
Figure 4. Time course of efficacy following a single oral dose of GSM compound 3. Male C57Bl6 mice (n = 7/time point) were dosed with 10 mg/kg of compound 3 or vehicle by oral gavage. Animals were then sacrificed at the indicated time point (1–48 h), and the levels of Aβ42 and Aβ40 peptides in plasma and brain extracts were quantified using Meso Scale Sector 6000 Multiplex assays. Data are expressed in picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; ****, P < 0.0001. ND, below detectable limit of the assay.CC BY-NC-SA · PubMed Central
Figure 5. Effects of chronic treatment with GSM compound 2 on Aβ peptides in 6-mo-old and 9-mo-old PSAPP mice. (A–F) Levels of Aβ42, Aβ40, and Aβ38 in plasma and brain following oral administration of either vehicle (Veh) or compound 2 (cmpd 2) for 3 consecutive mo to 3-mo-old or 6-mo-old APP/PS1 transgenic mice. Animals were dosed with vehicle or compound 2 (25 mg/kg/d po) and euthanized at 6 mo of age or 9 mo of age. n = 8/age vehicle; n = 8/age compound 2. The levels of Aβ42, Aβ40, and Aβ38 peptides in the 6-mo-old PSAPP mice were quantitated in plasma (A), RIPA detergent-soluble brain extracts (B), and formic acid–soluble, detergent-insoluble brain extracts (C). The levels of Aβ42, Aβ40, and Aβ38 peptides in the 9-mo-old PSAPP mice were quantitated in plasma (D), RIPA detergent-soluble brain extracts (E), and formic acid–soluble, detergent-insoluble brain extracts (F). Aβ peptides were measured using Meso Scale Sector 6000 Multiplex assays. Data are expressed as picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0005.
Figure 5. Effects of chronic treatment with GSM compound 2 on Aβ peptides in 6-mo-old and 9-mo-old PSAPP mice. (A–F) Levels of Aβ42, Aβ40, and Aβ38 in plasma and brain following oral administration of either vehicle (Veh) or compound 2 (cmpd 2) for 3 consecutive mo to 3-mo-old or 6-mo-old APP/PS1 transgenic mice. Animals were dosed with vehicle or compound 2 (25 mg/kg/d po) and euthanized at 6 mo of age or 9 mo of age. n = 8/age vehicle; n = 8/age compound 2. The levels of Aβ42, Aβ40, and Aβ38 peptides in the 6-mo-old PSAPP mice were quantitated in plasma (A), RIPA detergent-soluble brain extracts (B), and formic acid–soluble, detergent-insoluble brain extracts (C). The levels of Aβ42, Aβ40, and Aβ38 peptides in the 9-mo-old PSAPP mice were quantitated in plasma (D), RIPA detergent-soluble brain extracts (E), and formic acid–soluble, detergent-insoluble brain extracts (F). Aβ peptides were measured using Meso Scale Sector 6000 Multiplex assays. Data are expressed as picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0005.CC BY-NC-SA · PubMed Central
Figure 6. Lack of effect of chronic treatment with GSM compound 2 in PSAPP mice on APP (FL)/tubulin, α-CTF/tubulin, and β-CTF/tubulin ratios. (A–C) Quantitation of APP (FL)/tubulin ratios (A), α-CTF/tubulin ratios (B), and β-CTF/tubulin ratios (C) in 6-mo-old and 9-mo-old PSAPP mouse brain extracts following chronic treatment with either vehicle (V) or compound 2 (Cmpd 2) via Bio-Rad ImageLab software. Statistical analysis was performed using GraphPad Prism software, and the results are expressed as the mean of the ratio (black horizontal line) ± SEM. (D) Immunoblots of PSAPP brain extracts from 6-mo-old or 9-mo-old PSAPP mice treated with either vehicle (V) or compound 2 (2). Blots were probed for APP (FL), α-CTFs, β-CTFs, and tubulin using anti-carboxyl terminal APP and anti-tubulin antibodies.
Figure 6. Lack of effect of chronic treatment with GSM compound 2 in PSAPP mice on APP (FL)/tubulin, α-CTF/tubulin, and β-CTF/tubulin ratios. (A–C) Quantitation of APP (FL)/tubulin ratios (A), α-CTF/tubulin ratios (B), and β-CTF/tubulin ratios (C) in 6-mo-old and 9-mo-old PSAPP mouse brain extracts following chronic treatment with either vehicle (V) or compound 2 (Cmpd 2) via Bio-Rad ImageLab software. Statistical analysis was performed using GraphPad Prism software, and the results are expressed as the mean of the ratio (black horizontal line) ± SEM. (D) Immunoblots of PSAPP brain extracts from 6-mo-old or 9-mo-old PSAPP mice treated with either vehicle (V) or compound 2 (2). Blots were probed for APP (FL), α-CTFs, β-CTFs, and tubulin using anti-carboxyl terminal APP and anti-tubulin antibodies.CC BY-NC-SA · PubMed Central
Figure 7. Effects of chronic treatment with GSM compound 2 on amyloid deposition and microgliosis of 6-mo-old and 9-mo-old PSAPP mice. (A) Representative sagittal sections immunostained with mAb 3D6 and counterstained with Iba1 from PSAPP mice treated with either vehicle (Veh) or compound 2 (Cmpd 2) at a dose of 25 mg/kg/d for 3 mo beginning at either 3 mo of age (6-mo-old mice) or 6 mo of age (9-mo-old mice). n = 5/age group vehicle; n = 5/age group compound 2. (B) Quantitation of amyloid deposition (mAb 3D6) and microgliosis (Iba1) imaged in the cortex and hippocampus at either 6 mo of age or 9 mo of age following 3 mo of treatment with either vehicle or compound 2. Statistical analysis was performed using GraphPad Prism software, and the results are expressed as the mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) Correlation analyses between mAb 3D6 immunostaining and Iba1 staining in 6-mo-old and 9-mo-old PSAPP mice following 3 mo of treatment with either vehicle or compound 2. Statistical analysis was performed with one-way ANOVA post hoc Tukey analysis.
Figure 7. Effects of chronic treatment with GSM compound 2 on amyloid deposition and microgliosis of 6-mo-old and 9-mo-old PSAPP mice. (A) Representative sagittal sections immunostained with mAb 3D6 and counterstained with Iba1 from PSAPP mice treated with either vehicle (Veh) or compound 2 (Cmpd 2) at a dose of 25 mg/kg/d for 3 mo beginning at either 3 mo of age (6-mo-old mice) or 6 mo of age (9-mo-old mice). n = 5/age group vehicle; n = 5/age group compound 2. (B) Quantitation of amyloid deposition (mAb 3D6) and microgliosis (Iba1) imaged in the cortex and hippocampus at either 6 mo of age or 9 mo of age following 3 mo of treatment with either vehicle or compound 2. Statistical analysis was performed using GraphPad Prism software, and the results are expressed as the mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) Correlation analyses between mAb 3D6 immunostaining and Iba1 staining in 6-mo-old and 9-mo-old PSAPP mice following 3 mo of treatment with either vehicle or compound 2. Statistical analysis was performed with one-way ANOVA post hoc Tukey analysis.CC BY-NC-SA · PubMed Central
Figure 8. Correlation analyses of effects of GSM compound 2 treatment on Aβ peptides in brain, CSF, and plasma. (A–D) Correlation analysis of Aβ40 between brain and plasma (A) and between brain and CSF (B) in Sprague-Dawley rats treated with compound 2. Correlation analysis of Aβ42 between brain and plasma (C) and between brain and CSF (D) in Sprague-Dawley rats treated with compound 2. Data were plotted from Table S2 and analyzed by Pearson correlation analysis. (A) Scatter plot for brain Aβ40 and plasma Aβ40 from individual rats (total of 56 rats). Linear regression showed a best fit of y = 1.098*x − 21.88, r2 = 0.8326, P < 0.0001. (B) Scatter plot for brain Aβ40 and CSF Aβ40 from individual rats (total of 53 rats). Linear regression showed a best fit of y = 0.9595*x + 2.267, r2 = 0.6923, P < 0.0001. (C) Scatter plot for brain Aβ42 and plasma Aβ42 from individual rats (total of 47 rats). Linear regression showed a best fit of y = 0.8637*x + 1.723, r2 = 0.7618, P < 0.0001. (D) Scatter plot for brain Aβ42 and CSF Aβ42 from individual rats (total of 53 rats). Linear regression showed a best fit of y = 0.8056*x + 18.60, r2 = 0.6606, P < 0.0001. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect.
Figure 8. Correlation analyses of effects of GSM compound 2 treatment on Aβ peptides in brain, CSF, and plasma. (A–D) Correlation analysis of Aβ40 between brain and plasma (A) and between brain and CSF (B) in Sprague-Dawley rats treated with compound 2. Correlation analysis of Aβ42 between brain and plasma (C) and between brain and CSF (D) in Sprague-Dawley rats treated with compound 2. Data were plotted from Table S2 and analyzed by Pearson correlation analysis. (A) Scatter plot for brain Aβ40 and plasma Aβ40 from individual rats (total of 56 rats). Linear regression showed a best fit of y = 1.098*x − 21.88, r2 = 0.8326, P < 0.0001. (B) Scatter plot for brain Aβ40 and CSF Aβ40 from individual rats (total of 53 rats). Linear regression showed a best fit of y = 0.9595*x + 2.267, r2 = 0.6923, P < 0.0001. (C) Scatter plot for brain Aβ42 and plasma Aβ42 from individual rats (total of 47 rats). Linear regression showed a best fit of y = 0.8637*x + 1.723, r2 = 0.7618, P < 0.0001. (D) Scatter plot for brain Aβ42 and CSF Aβ42 from individual rats (total of 53 rats). Linear regression showed a best fit of y = 0.8056*x + 18.60, r2 = 0.6606, P < 0.0001. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect.CC BY-NC-SA · PubMed Central
Figure 9. Efficacy of GSM compound 2 on various Aβ peptide levels in plasma of NHPs. (A) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/dose) at 4 h following a single nasogastric dose of 0 mg/kg (vehicle), 10 mg/kg (mean plasma [drug] = 753 ng/ml), 30 mg/kg (mean plasma [drug] = 1,235 ng/ml), 100 mg/kg (mean plasma [drug] = 2,895 ng/ml), or 200 mg/kg (mean plasma [drug] = 2,475 ng/ml). (B) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/time point) following a single nasogastric dose (200 mg/kg) on day 1 of the repeat-dosing phase in the DRF toxicokinetic study measured at 0 h (mean plasma [drug] = LLOQ), 1 h (mean plasma [drug] = 109 ng/ml), 2 h (mean plasma [drug] = 460 ng/ml), 4 h (mean plasma [drug] = 2,300 ng/ml), 8 h (mean plasma [drug] = 2,560 ng/ml), or 24 h (mean plasma [drug] = 1,705 ng/ml) after drug or vehicle administration. Aβ38, Aβ40, and Aβ42 peptides were quantitated using Meso Scale Sector 6000 Multiplex assays. Data are expressed as picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 9. Efficacy of GSM compound 2 on various Aβ peptide levels in plasma of NHPs. (A) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/dose) at 4 h following a single nasogastric dose of 0 mg/kg (vehicle), 10 mg/kg (mean plasma [drug] = 753 ng/ml), 30 mg/kg (mean plasma [drug] = 1,235 ng/ml), 100 mg/kg (mean plasma [drug] = 2,895 ng/ml), or 200 mg/kg (mean plasma [drug] = 2,475 ng/ml). (B) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/time point) following a single nasogastric dose (200 mg/kg) on day 1 of the repeat-dosing phase in the DRF toxicokinetic study measured at 0 h (mean plasma [drug] = LLOQ), 1 h (mean plasma [drug] = 109 ng/ml), 2 h (mean plasma [drug] = 460 ng/ml), 4 h (mean plasma [drug] = 2,300 ng/ml), 8 h (mean plasma [drug] = 2,560 ng/ml), or 24 h (mean plasma [drug] = 1,705 ng/ml) after drug or vehicle administration. Aβ38, Aβ40, and Aβ42 peptides were quantitated using Meso Scale Sector 6000 Multiplex assays. Data are expressed as picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 88

Metadata

Authors
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., Florio, J., Mante, M., Salehi, B., Arias, C., Galasko, D., Head, B. P., Johnson, G., Lin, J. H., Duddy, S. K., Rissman, R. A., Mobley, W. C., Thinakaran, G., Tanzi, R. E., & Wagner, S. L.
Affiliations
  • University of California San Diego (US)
  • University of South Florida (US)
  • Massachusetts General Hospital (US)
  • Veterans Health Administration (US)
  • NuPharmAdvise, Sanbornton, NH 6
  • Seven (CZ)
  • Integrated Nonclinical Development Solutions (United States) (US)
Corresponding author
Wagner, Steven L.
Venue
Journal of Experimental Medicine
Published
2021-03-02
Volume
218
Issue
4
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3135208068
Cited by
76
References
46
Citations by year
2026: 11 · 2025: 8 · 2024: 17 · 2023: 11 · 2022: 17 · 2021: 11
FWCI
10.21
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
Funders
  • Cure Alzheimer’s Fund
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging (NS 074501, U01AG048986, R01AG055523, R01AG054223, R01AG056061)
  • National Institutes of Health
  • Chen Foundation (R-86U55A)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
γ-secretase modulators, Alzheimer's disease prevention, early-onset familial Alzheimer's disease, amyloid-beta 42, gamma-secretase inhibitors, allosteric modulation, transgenic mouse model, preclinical safety, dose-dependent efficacy, primary prevention
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Female, Humans, Macaca fascicularis, Male, Mice, Inbred C57BL, Mice, Transgenic, Neuroblastoma, Peptide Fragments, Phenethylamines, Pyridazines, Signal Transduction, Amyloid beta-Peptides, Treatment Outcome, Rats, Sprague-Dawley, Cell Line, Tumor, Mice, Rats, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.